高级检索
当前位置: 首页 > 详情页

Inflammatory response is modulated by lincRNACox2 via the NF-kappa B pathway in macrophages infected by Mycobacterium tuberculosis

文献详情

资源类型:
WOS体系:

收录情况: ◇ SCIE

单位: [1]Department of Pulmonary and Critical Care Medicine, China‑Japan Friendship Hospital, Beijing 100029 [2]Department of Respiration, Hongda Hospital of Jiamusi University, Jiamusi, Heilongjiang 154004 [3]Department of Pathology, China‑Japan Friendship Hospital, Beijing 100029, P.R. China
出处:
ISSN:

关键词: lincRNACox2 Mycobacterium tuberculosis macrophages NF-kappa B

摘要:
Long intergenic non-coding RNAs (lincRNAs) are long non-coding transcripts from the intergenic regions of annotated protein-coding genes. lincRNA cyclooxygenase 2 (Cox2) is an early-primary response gene regulated by the NF-kappa B signaling pathway in macrophages. It was found that lincRNACox2 was significantly increased in patients with the Mycobacterium tuberculosis (M. tuberculosis) H37Ra strain infection and macrophages, using reverse transcription-quantitative PCR (RT-qPCR). ELISA, western blotting and RT-qPCR results indicated that the inflammatory response factors tumor necrosis factor-alpha, interferon-gamma, interleukin-6, Cox2 and inducible nitric oxide synthase were significantly increased in H37Ra infected macrophages. In addition, the inflammatory regulating proteins NF-kappa B and Stat3 were significantly increased in H37Ra infected macrophages but decreased in lincRNACox2 knockdown macrophages infected with H37Ra. Moreover, the knockdown of lincRNACox2 increased the apoptotic rate of H37Ra infected macrophages and facilitated the proliferation of H37Ra. Collectively, the present results suggested that lincRNACox2 may be required for the activation of NF-kappa B and Stat3, in order to regulate inflammatory responses involved in resistance to M. tuberculosis infection.

语种:
被引次数:
WOS:
中科院(CAS)分区:
出版当年[2019]版:
大类 | 4 区 医学
小类 | 4 区 医学:研究与实验 4 区 肿瘤学
最新[2025]版:
大类 | 4 区 医学
小类 | 4 区 医学:研究与实验 4 区 肿瘤学
JCR分区:
出版当年[2018]版:
Q3 MEDICINE, RESEARCH & EXPERIMENTAL Q4 ONCOLOGY
最新[2023]版:
Q2 MEDICINE, RESEARCH & EXPERIMENTAL Q2 ONCOLOGY

影响因子: 最新[2023版] 最新五年平均[2021-2025] 出版当年[2018版] 出版当年五年平均[2014-2018] 出版前一年[2017版] 出版后一年[2019版]

第一作者:
第一作者单位: [1]Department of Pulmonary and Critical Care Medicine, China‑Japan Friendship Hospital, Beijing 100029
共同第一作者:
通讯作者:
通讯机构: [1]Department of Pulmonary and Critical Care Medicine, China‑Japan Friendship Hospital, Beijing 100029 [*1]Department of Pulmonary and Critical Care Medicine, China‑Japan Friendship Hospital, 2 East Yinghua Road, Chaoyang, Beijing 100029, P.R. China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:1320 今日访问量:0 总访问量:816 更新日期:2025-04-01 建议使用谷歌、火狐浏览器 常见问题

版权所有:重庆聚合科技有限公司 渝ICP备12007440号-3 地址:重庆市两江新区泰山大道西段8号坤恩国际商务中心16层(401121)